Litcius/Paper detail

Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients

Belén Atienza‐Mateo, Ana Serrano-Combarro, Jesus Loarce‐Martos, N. Vegas-Revenga, María Martín-López, Santos Castañeda, R. González, Natalia Mena‐Vázquez, Carmen Carrasco Cubero, Carolina Díez Morrondo, David Castro Corredor, Tomás Ramón Vázquez Rodríguez, Antônio Carlos Francesconi do Valle, Gema Bonilla, Marina Rodríguez López, Ignacio Braña Abascal, Sara María Rojas Herrera, Juan Camilo Sarmiento-Monroy, Pablo Andújar Brazal, Diego Ferrer, Iván Ferraz‐Amaro, Ricardo Blanco, Delia Fernández Lozano, Cristina Arciniega Larios, Juan Ramón de Dios, Libe Ibarrola, Carmen Gonzalez Montagut, Sergi Ordoñez, Anahy María Brandy-García, Fernando Lozano Morillo, María López Lasanta, Cristina Campos, Marta Garijo Bufort, Ivette Casafont Solé, Mónica Calderón Goercke, Carlota Iñiguez Ubiaga, Francisco Ortiz-Sanjuán, Emilio Giner Serret, Ángela Pecondon Español, Bryan Josué Flores Robles, Mireia Moreno, Virginia Ruiz-Esquide, Evelin Cecilia Cervantes Pérez, Christian Omar Anchorena Diaz

2025Seminars in Arthritis and Rheumatism12 citationsDOI

Topics & Concepts

MedicineNintedanibInterstitial lung diseaseRheumatoid arthritisInternal medicineMulticenter studyLung diseaseIdiopathic pulmonary fibrosisLungRandomized controlled trialInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisRheumatoid Arthritis Research and TherapiesInflammatory Myopathies and Dermatomyositis